Donor Blood Cell-based Platform

Unlike the commonly used αβ T cells that are restricted to autologous application only, γδ T cells may provide a potent “off-the-shelf” cytotoxic cell source to treat cancers in different recipients without causing graft-versus-host disease.

CytoMed’s donor blood cell-based CAR-γδ T cell technology

Industry-friendly features of our CAR-γδ T cell technology

OTHERS

CYTOMED

Technology Features

CAR-αβ T cell technology

CAR-γδ T cell technology

Source of starting material

Patient’s blood cells, potential issues include Limited cell number due to leukopenia or young age Poor cell quality due patient’s conditions or previous treatments Contamination of leukaemia cells or circulating tumour cells

Healthy donor’s blood cells, advantages include Guaranteed cell number Reasonable cell quality No contamination of cancer cells

Collection of starting material

Invasive leukapheresis to collect immune cells

Simple blood draw to collect blood sample

Manufacturing process

Complicated manufacturing process include Washing leukocytes out of apheresis products using a cell washer Enriching lymphocytes via counterflow centrifugal elutriation expanding and transducing T cells using beads and lentiviral vectors

Simpler manufacturing process include mononuclear cell isolation γδ T cell expansion mRNA electroporation

Method to introduce CAR

Lentivirus, potential issues include The risk of secondary cancers due to insertional mutagenesis in CAR-αβ T cells or contamination of cancer cells The risk of long-term adverse effects due to persistence of CAR-αβ T cells

mRNA electroporation, advantages include No risk of secondary cancers No risk of long-term adverse effects

Final product

CAR-grafted αβ T cells

CAR-grafted γδ T cells

Scope of application

Autologous use, applicable to a single patient only

Allogeneic use, applicable to many patients

Industrial potential

Highly personalized “made-to-order” product, very expensive

“Off-the-shelf” product, less expensive